Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 5/20 | 0.65 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.54 |
| ▸ | ECE1 | P42892 | 1/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | CTSL | P07711 | 2/20 | 0.52 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.52 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5679006 | 1.00 | ACE (0.65) | ACEGPR139PTPN1CA2CA1 | |
| SCHEMBL9829353 | 0.92 | ACE (0.56) | ACEPTPN1CA2CA1GPR132 | |
| SCHEMBL9829356 | 0.92 | ACE (0.56) | ACEPTPN1CA2CA1GPR132 | |
| SCHEMBL11023523 | 0.92 | ACE (0.56) | ACEGPR139PTPN1CA2CA1 | |
| SCHEMBL29511639 | 0.91 | SLC6A9 (0.63) | ACEGPR139PTPN1CA2SLC6A9 | |
| SCHEMBL11022457 | 0.87 | FPR2 (0.60) | ACEGPR139PTPN1CA2SLC6A9 | |
| SCHEMBL11022464 | 0.87 | PTPN1 (0.62) | ACEGPR139PTPN1CA2SLC6A9 | |
| SCHEMBL10950139 | 0.86 | CA1 (0.60) | ACEPTPN1CA2CA1MME | |
| SCHEMBL9829021 | 0.85 | OPRM1 (0.62) | MMECTSL | |
| SCHEMBL9829089 | 0.85 | OPRM1 (0.62) | MMECTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180008621-A1 | SELECTIVE HIGH-AFFINITY POLYDENTATE LIGANDS AND METHODS OF MAKING SUCH | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) | 2018-01-11 | — | — | US | claimed |
| US-20180008622-A1 | SELECTIVE HIGH-AFFINITY POLYDENTATE LIGANDS AND METHODS OF MAKING SUCH | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) | 2018-01-11 | — | — | US | claimed |
| US-20110144065-A1 | SELECTIVE HIGH-AFFINITY POLYDENTATE LIGANDS AND METHODS OF MAKING SUCH | U.S. DEPARTMENT OF ENERGY | 2011-06-16 | — | — | US | claimed |
| CN-102083850-A | Selective high-affinity polydentate ligands and methods for making same | UNIV CALIFORNIA | 2011-06-01 | — | — | CN | claimed |
| EP-2268654-A2 | SELECTIVE HIGH-AFFINITY POLYDENTATE LIGANDS AND METHODS OF MAKING SUCH | The Regents of the University of California (US) | 2011-01-05 | — | — | EP | claimed |
| WO-2009132020-A2 | SELECTIVE HIGH-AFFINITY POLYDENTATE LIGANDS AND METHODS OF MAKING SUCH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-10-29 | — | — | WO | claimed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | claimed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | claimed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | claimed |
| EP-0083857-B1 | DERIVATIVES OF HIPPURYL-L-PHENYLALANINE AND THEIR USE IN DETERMINING THE ACTIVITY OF CARBOXYPEPTIDASE A | FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. (JP) | 1985-06-05 | — | — | EP | claimed |
| US-4432896-A | Derivatives of hippuryl-L-phenylalanine | FUJIREBIO KABUSHIKI KAISHA (JP) | 1984-02-21 | — | — | US | claimed |
| EP-0083857-A1 | Derivatives of hippuryl-L-phenylalanine and their use in determining the activity of carboxypeptidase A | FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. (JP) | 1983-07-20 | — | — | EP | claimed |
| US-20230042729-A1 | PEPTIDE CONSTRUCTS AND COMPOSITIONS | DIET4LIFE APS (DK) | 2023-02-09 | — | — | US | disclosed |
| US-11285165-B2 | Selective high-affinity polydentate ligands and methods of making such | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) | 2022-03-29 | — | — | US | disclosed |
| US-20210106677-A1 | VACCINE DEVELOPMENT METHODOLOGY BASED ON AN ADHESION MOLECULE | MATSFIDE, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| US-20210000843-A1 | SELECTIVE HIGH-AFFINITY POLYDENTATE LIGANDS AND METHODS OF MAKING SUCH | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) | 2021-01-07 | — | — | US | disclosed |
| US-4432896-A | Derivatives of hippuryl-L-phenylalanine | FUJIREBIO KABUSHIKI KAISHA (JP) | 1984-02-21 | — | — | US | disclosed |
| EP-0083857-A1 | Derivatives of hippuryl-L-phenylalanine and their use in determining the activity of carboxypeptidase A | FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. (JP) | 1983-07-20 | — | — | EP | disclosed |
| EP-0083857-A1 | Derivatives of hippuryl-L-phenylalanine and their use in determining the activity of carboxypeptidase A | FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. (JP) | 1983-07-20 | — | — | EP | disclosed |
| EP-0083857-A1 | Derivatives of hippuryl-L-phenylalanine and their use in determining the activity of carboxypeptidase A | FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. (JP) | 1983-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11285165-B2 | Selective high-affinity polydentate ligands and methods of making such | CD44, FCGR3B, FCGR2A | ACE 4417/4885GPR139 3309/4885PTPN1 1873/4885 |
| US-20110144065-A1 | SELECTIVE HIGH-AFFINITY POLYDENTATE LIGANDS AND METHODS OF MAKING SUCH | CD44, FCGR3B, FCGR2A | ACE 4417/4885GPR139 3309/4885PTPN1 1873/4885 |
| US-20180008621-A1 | SELECTIVE HIGH-AFFINITY POLYDENTATE LIGANDS AND METHODS OF MAKING SUCH | CD44, FCGR3B, FCGR2A | ACE 4417/4885GPR139 3309/4885PTPN1 1873/4885 |
| US-20180008622-A1 | SELECTIVE HIGH-AFFINITY POLYDENTATE LIGANDS AND METHODS OF MAKING SUCH | CD44, FCGR3B, FCGR2A | ACE 4417/4885GPR139 3309/4885PTPN1 1873/4885 |
| US-20210000843-A1 | SELECTIVE HIGH-AFFINITY POLYDENTATE LIGANDS AND METHODS OF MAKING SUCH | CD44, FCGR3B, FCGR2A | ACE 4417/4885GPR139 3309/4885PTPN1 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.